Genzyme Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program
Genzyme, a Sanofi company, has launched the fifth annual Patient Advocacy Leadership Awards program for non-profit organizations that serve the lysosomal storage disorder (LSD) patient community.
PRESS RELEASE
CAMBRIDGE, Mass.--(
)--
, a Sanofi company, has launched the fifth annual Patient Advocacy Leadership (PAL) Awards program for non-profit organizations that serve the lysosomal storage disorder (LSD) patient community. The PAL Awards program seeks to spark innovative collaborations in disease awareness programs and patient support initiatives around the world. Genzyme’s Patient Advocacy Leadership Awards (PAL Awards) program is open to non-profit organizations that serve the lysosomal storage disorder (LSD) patient community and designed to support disease awareness programs and patient support initiatives around the world.
Through this competitive program, funds are granted to nonprofit, charitable patient organizations that seek funding for new initiatives that support the LSD community. In its fifth year, the program is evolving in 2015 to focus more on initiatives that involve two or more organizations collaborating together to support their broader LSD community, including regional and country collaborations and across various disease communities. The goal is to highlight and support programs that enable knowledge and best practice sharing, and work to unite the broader LSD community. For the first time this year, translation services will be provided to patient organizations seeking to apply in languages other than English. Submissions will be accepted now through September 30, 2015, when an External Review Committee will evaluate and select recipients. A total of $50,000 will be awarded through this year’s program.
“Patient organizations play a vital role in facilitating access to care and provide support for patients and their families around the world, and therefore supporting their work is critical to optimizing patient care and increasing disease awareness,” said Genzyme’s Head of Global Rare Diseases, Richard Peters, MD, Ph.D. “From travelling photo exhibits and video projects, to digital technology applications and mentoring programs, previous grant recipients have demonstrated their creativity, intensity and passion to improve the lives of patients living with LSDs through their submissions. We look forward to supporting more of these great efforts.”
Since 2011, more than $400,000 has been awarded to 37 patient organizations around the world to support disease awareness, community mobilization, non-profit development and good governance activities. For more information on the Genzyme PAL Awards program, or to apply for a grant, please visit
.
